Clinical Trial Update: Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update shows the study of IRX4204 combined with erlotinib in previously treated advanced non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IRX4204
• Tarceva (erlotinib)

Snippet

Sponsor: Io Therapeutics | Conditions: Lung Cancer, Nonsmall Cell | Phase 1 | Status: TERMINATED